PubAg

Main content area

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

Author:
Takeda, Kazuyoshi, Kojima, Yuko, Ikejima, Kenichi, Harada, Kenichi, Yamashina, Shunhei, Okumura, Kyoko, Aoyama, Tomonori, Frese, Steffen, Ikeda, Hiroko, Haynes, Nicole M., Cretney, Erika, Yagita, Hideo, Sueyoshi, Noriyoshi, Sato, Nobuhiro, Nakanuma, Yasuni, Smyth, Mark J., Okumura, Ko
Source:
Proceedings of the National Academy of Sciences of the United States of America 2008 v.105 no.31 pp. 10895-10900
ISSN:
0027-8424
Subject:
apoptosis, bile ducts, cholestasis, death, fibrosis, gene expression, humans, liver, liver failure, mice, monoclonal antibodies, patients
Abstract:
Chronic cholestasis often results in premature death from liver failure with fibrosis; however, the molecular mechanisms contributing to biliary cirrhosis are not demonstrated. In this article, we show that the death signal mediated by TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/death receptor 5 (DR5) may be a key regulator of cholestatic liver injury. Agonistic anti-DR5 monoclonal antibody treatment triggered cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury in a mouse strain-specific manner. TRAIL- or DR5-deficient mice were relatively resistant to common bile duct ligation-induced cholestasis, and common bile duct ligation augmented DR5 expression on cholangiocytes, sensitizing mice to DR5-mediated cholangitis. Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance, reminiscent of human primary sclerosing cholangitis. Human cholangiocytes constitutively expressed DR5, and TRAIL expression and apoptosis were significantly elevated in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients. Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.
Agid:
2359721